Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

MEI Pharma, Inc. (MEIP)

Pharmaceutical Preparations

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

11455 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/18/2003

Market Cap

21,438,418

Shares Outstanding

6,660,000

Weighted SO

6,662,857

Total Employees

N/A

Upcoming Earnings

09/24/2024

Similar Tickers

MGTA --.--%

KZR --.--%

VINC --.--%

ATXI --.--%

ASMB --.--%

NLTX --.--%

TIL --.--%

CTMX --.--%

ACHL --.--%

Beta

0.7330

Last Div

1.7500

Range

2.73-7.87

Chg

0.0476

Avg Vol

104614

Mkt Cap

21438418

Exch

NASDAQ

Country

US

Phone

858 369 7100

DCF Diff

N/A

DCF

1.8846

Div Yield

0.5439

P/S

0.3212

EV Multiple

1.3483

P/FV

0.4201

Div Yield %

54.3884

P/E

0.8197

PEG

0.0196

Payout

0.8916

Current Ratio

6.1737

Quick Ratio

6.1737

Cash Ratio

0.2463

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1059.6344

CCC

-1059.6344

Gross Margin

0.9836

Op Margin

0.3362

Pretax Margin

0.3918

Net Margin

0.3918

Eff Tax Rate

-0.0825

ROA

0.3670

ROE

0.4832

ROCE

0.3641

NI/EBT

1.0000

EBT/EBIT

1.1654

EBIT/Rev

0.3362

Debt Ratio

0.1637

D/E

0.2286

LT Debt/Cap

0.1722

Total Debt/Cap

0.1861

Int Coverage

-1726.3077

CF/Debt

-3.7521

Equity Multi

1.3965

Rec Turnover

0.0000

Pay Turnover

0.3445

Inv Turnover

0.0000

FA Turnover

5.6124

Asset Turnover

0.9368

OCF/Share

-6.5700

FCF/Share

-6.5658

Cash/Share

8.4875

OCF/Sales

-0.6558

FCF/OCF

0.9994

CF Coverage

-3.7521

ST Coverage

-41.6122

CapEx Coverage

-1563.4286

Div&CapEx Cov

-1.8749

P/BV

0.4201

P/B

0.4201

P/S

0.3212

P/E

0.8197

P/FCF

-0.4900

P/OCF

-0.4897

P/CF

-0.4897

PEG

0.0196

P/S

0.3212

EV Multiple

1.3483

P/FV

0.4201

DPS

1.7500

Latest Headlines (EST)

Zacks Investment Research Nov 01, 11:46 Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
1.75 11/16/2023 11/06/2023 11/17/2023 12/06/2023